"China has always been an important market for Novo Nordisk."
The Danish pharmaceutical company announced earlier this week that it will increase investment in its production base in China's Tianjin by about 4 billion yuan (about 556 million U.S. dollars). #GLOBALink
Produced by Xinhua Global Service
